You know already about the promise for CRISPR-Cas9 — it might revolutionize fields from medicine to agriculture.
It might also eventually cause tumors.
So far, the digital revolution has mostly been a disappointment in health care. Doctors stare at their screens instead of us. Specialists and emergency rooms still don’t have all our records.
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense (DoD). The award of $150,000 will support the Company’s ongoing efforts to develop its NSI-566 human neural stem cell line as a candidate therapeutic for severe Traumatic Brain Injury (TBI).
Maryland Technology Development Corp. is launching a new fund that will offer early stage investments of $50,000 to startups that may be overlooked by other funding organizations.
Biotechnology is one of the hottest areas in business and investing, so it might seem a bit counterintuitive that a new biotechnology firm just launched that won’t seek to make any profit. But the new nonprofit drugmaker seeks to do precisely that, in order to tackle some of the worst health crises in the developing world.
Eight US-based startups have been accepted onto the 2018 cohort of Trajectory Next, a second-stage accelerator run by Johns Hopkins University (JHU), University of Maryland, Baltimore (UMB) and incubator Betamore.
Perhaps it was inevitable that with Food and Drug Administration Commissioner Scott Gottlieb speaking before an auditorium full of biotechnology executives, a particularly contentious topic would come up: the new right-to-try law.
Lockheed Martin [LMT] on Wednesday said it has added another $100 million to its venture capital fund, doubling the firepower of Lockheed Martin Ventures for investments in early-stage companies that are developing advanced technologies.
Regulatory and competitive uncertainties in the marketplace lead many life sciences companies to enter into collaborative arrangements with other companies to develop new drugs or medical devices. These arrangements allow for the leverage of expertise that may not have been available in-house – such as a pharmaceutical company that sees promising new science from a biotech startup – while also sharing in the costs and risks of new product development.
Betamore, Johns Hopkins Technology Ventures and the University of Maryland, Baltimore have launched the first cohort of a new collaborative accelerator program, called Trajectory Next.